Regenerative medicine has huge potential for Germany, finds study
Germany is leading the way in regenerative medicine, but must do more to remove barriers and ensure that the results of research find their way into the market, according to a new study published by the German Ministry for Education and Research. Regenerative medicine is an emerging field involving biology, medicine, and engineering. It may well revolutionise the ways in which patients are treated by restoring, maintaining, or enhancing tissue and organ function. The report finds that Germany has done the scientific ground work, investing €230 million since 1990. However, some of the research conducted is not being turned into products or therapies, and potential is therefore being lost. The report's authors, from Capgemini, suggest that the problems are due to the way in which costs are refunded through health insurance funds, the approval procedure for medical products, and the requirements for clinical studies. These framework conditions differ from country to country, and have an enormous influence on how and whether a product is used commercially. The burden, as usual, is felt the most by small and medium-sized enterprises (SMEs). The study focused on medical developments that are expected to be ready for the market within five years. These include: skin replacement products for chronic wounds, cell therapy for repairing the liver, and for repairing bone defects close to joints, which could have a value of €150 million per year in a few years, predicts the study. An even larger market is predicted for the relatively new research area of indicators of myocardial infarctions and congestive heart failure. Using replacement cells to repair damaged sections of the heart, and creating cultured heart valves could provide a turnover of €1 billion within the next few years, the report predicts. The rising number of patent applications gives an indication of the short-term market potential of this research field. In order to accelerate medical treatment, the report recommends that those applying for research grants give a stronger indication of market potential in their research proposals. More funding should also be provided for studies looking for evidence of cost-use-efficiency. Research experts should also work more closely with the research funders or sponsors in networks. Finally, the report notes the importance of the planned EU-wide authorisation procedures for regenerative medicine products, and the harmonisation of criteria for the reimbursement of costs.
Countries
Germany